CD52 and graft versus host disease: The TCR alpha constant gene is disrupted to reduce the risk of GVHD and the CD52 gene is disrupted with Transcription Activator-Like Effector Nucleases (Talen®) technology to permit the use of ALLO-647, an anti-CD52 mAb, for selective and prolonged host lymphodepletion [50].